- Home
- SEZL vs LIVN Comparison
SEZL vs LIVN Comparison
Compare SEZL & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- LIVN
- Stock Information
- Founded
- SEZL 2016
- LIVN 1987
- Country
- SEZL United States
- LIVN United Kingdom
- Employees
- SEZL N/A
- LIVN N/A
- Industry
- SEZL Diversified Financial Services
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SEZL Finance
- LIVN Health Care
- Exchange
- SEZL Nasdaq
- LIVN Nasdaq
- Market Cap
- SEZL 1.8B
- LIVN 2.1B
- IPO Year
- SEZL N/A
- LIVN 1993
- Fundamental
- Price
- SEZL $74.98
- LIVN $44.07
- Analyst Decision
- SEZL Strong Buy
- LIVN Buy
- Analyst Count
- SEZL 2
- LIVN 7
- Target Price
- SEZL $61.42
- LIVN $58.57
- AVG Volume (30 Days)
- SEZL 1.0M
- LIVN 851.4K
- Earning Date
- SEZL 05-07-2025
- LIVN 05-07-2025
- Dividend Yield
- SEZL N/A
- LIVN N/A
- EPS Growth
- SEZL 670.52
- LIVN N/A
- EPS
- SEZL 2.97
- LIVN N/A
- Revenue
- SEZL $329,060,890.00
- LIVN $1,275,437,000.00
- Revenue This Year
- SEZL $33.01
- LIVN $5.79
- Revenue Next Year
- SEZL $16.24
- LIVN $5.51
- P/E Ratio
- SEZL $25.26
- LIVN N/A
- Revenue Growth
- SEZL 91.69
- LIVN 7.63
- 52 Week Low
- SEZL $10.46
- LIVN $32.48
- 52 Week High
- SEZL $81.83
- LIVN $64.48
- Technical
- Relative Strength Index (RSI)
- SEZL 80.09
- LIVN 70.21
- Support Level
- SEZL $51.77
- LIVN $35.00
- Resistance Level
- SEZL $56.91
- LIVN $37.95
- Average True Range (ATR)
- SEZL 4.56
- LIVN 1.29
- MACD
- SEZL 2.10
- LIVN 0.93
- Stochastic Oscillator
- SEZL 84.51
- LIVN 94.84
About SEZL Sezzle Inc.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, primarily deriving revenue from payment processing platform in North America.
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.